Introduction
============

Whole or partial deletion of chromosomes 5 and 7 \[-5/del(5q) and -7/del(7q)\] are considered to be the most recurrent genetic abnormalities consisting of 10-20% of myeloid malignancies including both myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) [@B1]-[@B3]. It has been proposed that haploinsufficiency of tumor suppressor genes on the common deleted regions (CDRs) of chromosomes 5 and 7 contributes to the pathogenesis of MDS and AML[@B4],[@B5]. However, the exact mechanism and genes being affected are still under investigation [@B6]. The prognostic value of -5/del(5q) and -7/del(7q) as the sole abnormality is poor in most MDS and AML cases, except del(5q) syndrome in MDS that has a favorable prognosis [@B7]-[@B9]. Given that -5/del(5q) and/or -7/del(7q) often are accompanied with additional recurrent chromosomal alterations [@B10]-[@B12], genetic change(s) on the accompanying chromosome(s) other than chromosomes 5 and 7 may be important factor(s) affecting leukemogenesis and disease prognosis. Recently, it has been reported that alterations of the *XPD*and *TP53*genes were associated specifically with the risk of developing AML with -5/del(5q) and/or -7/del(7q) [@B13],[@B14]. Moreover, the significance of the co-existence of -5/del(5q) and -7/del(7q) in the progression of MDS and AML needs to be explored since \~40% of MDS and AML cases with-5/del(5q) also have -7/del(7q) [@B10],[@B11].

Therefore, using an integrated analysis of karyotype, fluorescence *in situ* hybridization (FISH) and array comparative genomic hybridization (CGH) results in the present study, we evaluated interesting genes in the smallest region of overlap (SRO) of chromosomes 5 and 7 as well as copy number alterations (CNAs) on the other chromosomes. Moreover, the link between the genomic alterations and del(5q) and/or -7/del(7q) was investigated by categorizing the cases into three groups based on the abnormalities of chromosomes 5 and 7. Group I consisted of cases only with del(5q), group II were cases only with -7/del(7q) and group III included the cases with concurrent del(5q) and del(7q).

Materials and Methods
=====================

Patient samples
---------------

This research project was approved by both the Ethical Committee of the First Affiliated Hospital of China Medical University and the Institutional Review Board (IRB) at the University of Oklahoma Health Sciences Center (OUHSC) (IRB\#13100).

Retrospectively, twenty six samples were collected from 2006 - 2010 at the Genetics Laboratory at OUHSC and found to be positive for del(5q) and/or -7/del(7q) by conventional cytogenetic, FISH and/or array CGH analyses. Of the 26 cases, twenty two were bone marrow and four were leukemic blood samples with initial diagnoses of MDS (n=6) or AML (n=20). The diagnosis was made according to the criteria of the French-American-British (FAB) Cooperative Group. The ratio of male to female patients was 17 to 9 and the median age of the patients was 59 years old, ranging from 2 to 73 years old (Table [S1](#SM1){ref-type="supplementary-material"}).

Conventional cytogenetics and FISH
----------------------------------

Overnight cultures of 22 \[unstimulated bone marrow (n=18) and leukemic blood (n=4)\] out of a total of 26 samples were established and harvested according to our standard laboratory protocols. Chromosome studies were not performed on the remaining four bone marrow samples because it was not requested by physicians. Chromosome preparations were treated and stained by Trypsin-Leishman (GTL) banding. The chromosomal abnormalities were described according to the International System for Human Cytogenetic Nomenclature (ISCN). Subsequent FISH analyses were performed on four cases (cases 4, 11, 15 and 18) using a series of probes which included LSID5S23, D5S721(5p15.2)/EGR1(5q31) (cases 4 and 15), LSI ELN(7q11.23)/D7S486(7q31)(cases 11, 15 and 18), CEP7 (case 15) (Abbott Molecular Inc., Des Plaines, IL) and homebrewed probe RP11-836E15 (21q22.3) (case 15) (BAC clone from Invitrogen Corporation, Carlsbad, CA) according to our standard laboratory protocols [@B15].

Array CGH
---------

Genomic DNA was isolated from all 26 samples using a commercially available DNA extraction kit (Puregene blood kit, QIAGEN Inc., Valencia, CA). The manufacturer\'s protocol was followed on a 720k oligonucleotides chip purchased from Roche/NimbleGen System Inc. (Madison, WI). Commercially available pooled normal control DNA was used for reference (Promega Corporation, Madison, WI). The patient DNA and the reference DNA were labeled with either Cyanine 3 (Cy-3) or Cyanine 5 (Cy-5) by random priming (Trilink Biotechnologies, San Diego, CA) and then hybridized to the chip via incubation in the MAUI hybridization system (BioMicro Systems, Salt Lake City, UT). After the 40-hour hybridization at 42°C, the slides were washed and scanned using a MS200 scanner (Roche NimbleGen System Inc., Madison, WI). NimbleScan version 2.4 and the SignalMap version 1.9 were applied for data analysis (NimbleGen System Inc, Madison, WI). The genomic locations were retrieved from the National Center for Biotechnology Information (NCBI) build 36 (hg 18). Frequently affected regions recently detected as copy number polymorphisms (CNPs) were excluded from data analysis according to the CNP database generated in our laboratory and the Database of Genomic Variants (<http://projects.tcag.ca/variation>).

Statistical analysis
--------------------

Correlation of genomic CNAs and del(5q) and/or -7/del(7q) were assessed using Fisher\'s exact test for qualitative variables and the Chi-square test for quantitative factors. All statistical analyses were performed using SPSS version 17.0 and a p-value ≤0.05 was considered statistically significant.

Results
=======

Grouping of del(5q) and/or -7/del(7q) by integrated analysis
------------------------------------------------------------

The integrated analysis of 26 cases positive for del(5q) and/or -7/del(7q) was performed by combining karyotype, FISH and array CGH results (Table [S1](#SM1){ref-type="supplementary-material"}). Of the 26 cases, four cases (cases 4, 11, 15 and 18) were analyzed by GTL banding, FISH and array CGH, 18 cases were analyzed by GTL banding and array CGH and four cases (cases 6, 17, 25 and 26) were analyzed only by array CGH. There is a discrepancy in the results of GTL banding and array CGH analyses due to the different levels of resolution of each technique. The cases determined to be monosomy 5 (cases 4, 5, 21 and 23) or monosomy 7 (cases 19, 21 and 24) by GTL banding analysis were further classified as del(5q), del(7q) or rearrangements involving chromosomes 5 or 7 by array CGH and/or FISH. Three cases originally defined as derivative chromosomes 5 (case 24) and 7 (cases 20 and 23) by GTL banding were also refined as del(5q) and del(7q) after array CGH analysis. The karyotype analysis of case 17 only showed constitutional trisomy 21 (Down syndrome), whereas array CGH not only confirmed the gain of chromosome 21 but also uncovered additional genomic imbalances, including the loss of chromosome 7 which was confirmed by FISH. Additionally, one case (case 3) with a del(5)(q31q35) determined by GTL banding analysis was re-designated as a large gain of 5p combined with a cryptic loss of 5q by array CGH. Based on the results and to better understand the association between CNAs and del(5q) and/or -7/del(7q), the cases were categorized into three groups based on the abnormalities of chromosomes 5 and 7. The first group consisted of six cases of del(5q), the second group included 11 cases with -7/del(7q) and the third group contained nine cases that had both del(5q) and del(7q).

Total CNAs detected by array CGH
--------------------------------

A total of 318 CNAs from 26 cases were observed with sizes ranging from 0.028Mb to 170.9 Mb which encompassing gene(s); 32.7% (104/318) of the CNAs were gains and 67.3% (214/318) of the CNAs were losses. Cryptic CNAs, sizes smaller than 5Mb, accounted for 50.9% (162/318), which were undetectable by GTL banding (Table [S2](#SM1){ref-type="supplementary-material"}, Figure [S1](#SM1){ref-type="supplementary-material"}). Of these cryptic CNAs, 63 were gains and 99 were losses. Since the average number of CNAs per case was 12 (ranging from 1 to 40), the cases with 12 or more CNAs were defined as high number (HN) CNAs. The ratio of the number of cases with HN CNAs to the number of total cases of each group was compared between the three groups (Table [1](#T1){ref-type="table"}). Group III had the most cases with HN CNAs; group II did not include any cases with HN CNAs. These two groups (II and III) were the only groups statistically different (p ≤0.05) from each other based on the Chi-square test results.

Delineation of SROs of del(5q) and -7/del(7q) in the three groups
-----------------------------------------------------------------

Genomic segmental losses of chromosome 5 were found in 15 cases consisting of six cases from group I and nine cases from group III (Table [S3](#SM1){ref-type="supplementary-material"}). Eight cases had a simple 5q deletion and seven cases had a complex deletion, defined as a deletion with more than two nonconsecutive deletions, of 5q. Monosomy (n=6) and genomic deletion (n=14) of chromosome 7 were observed in 20 cases, which included 11 cases from group II and nine cases from group III. Interestingly, all six cases of monosomy 7 belonged to group II. Of the other 14 cases, 12 cases were simple deletions of 7q and two cases were complex deletion of 7q. The SRO of chromosomes 5 and 7 in the three groups were mapped (Figure [1](#F1){ref-type="fig"}). The SRO of group I is 5q23.2-q33.2 (122,435,964-154,319,730bp: hg18) and \~ 32Mb in size. The SRO of group III is 5q31.1-33.1 (130,562,020-150,625,216bp: hg18) and \~ 20Mb in size, which is the common SRO of groups I and III of chromosome 5. The SRO of group II is 7q22.1-qter (102,913,354-158,816,034bp: hg18) and \~ 56Mb in size. The SRO of group III is 7q31.31-q36.1 (119,547,309-149,033,790bp: hg18) and \~ 29Mb in size, which is the common SRO of groups II and III of chromosome 7.

Delineation of \'other CNAs\' in the three groups
-------------------------------------------------

The CNAs on chromosomes other than chromosomes 5 and 7 were defined as \'other CNAs\'. A total of 249 \'other CNAs\', which accounted for \~ 78.3% of all the CNAs, were observed with a striking distribution throughout the genome, except on chromosome Y. The average number of \'other CNAs\' was 9.58 per case and thus, the cases with 10 or more \'other CNAs\' were defined as cases with HN \'other CNAs\' and \'other CNAs\' which occurred in at least two or more cases was defined as recurrent \'other CNAs\'. To characterize the features of the \'other CNAs\', several parameters, including 1) the average number of \'other CNAs\' per case, 2) the average number of recurrent \'other CNAs\' per case and 3) the ratio of cases with HN \'other CNAs\' to the number of total cases of each group, were compared between the three groups (Table [2](#T2){ref-type="table"}). Comparing groups II and III, significant differences (p\<0.05) were observed on all the parameters. Comparing groups I and III, no statistical difference (p≥0.05) was found on any parameter except the average number of recurrent \'other CNAs\'. Group I showed a significantly higher average number of \'other CNAs\' compared to group II. Of the 249 \'other CNAs\', 68 were recurrent \'other CNAs\' (Table [S4](#SM1){ref-type="supplementary-material"}, Figure [S2](#SM1){ref-type="supplementary-material"}). Notably, most of the recurrent \'other CNAs\' were found in group III (97.1%) and none were found in group II only. Moreover, 69.1% of the recurrent \'other CNAs\' were also cryptic CNAs and all of them found in group III. Interesting tumor-associated genes based on the known gene function from UCSC genome browser (<http://genome.ucsc.edu/>) and NCBI (<http://www.ncbi.nlm.nih.gov/gene/>) were selected and separately listed from recurrent \'other CNAs\' (Figure [2](#F2){ref-type="fig"}, Tables S5). From this additional analysis, genomic segmental losses of 3q21.1, 12p13.2, 12p13.1-p12.3 and 20q13.13 harboring *ADCY5, ETV6* (Figure [S3](#SM1){ref-type="supplementary-material"}A), *BCL2L14*, *RERG* and *PTPN1* were specially found in group III only. The most common segmental aberration in this study (5 cases) was the loss of various size of 17p harboring *TP53*(17p13.1) (Figure [S3](#SM1){ref-type="supplementary-material"}B), which was observed in both groups I and III. In addition, both gain (3 cases) and loss (2 cases) of 21q22.12, encompassing *RUNX1,*with various breakpoints was recurrently observed in all three groups.

Discussion
==========

It is important to understand precise and comprehensive genomic information for the diagnosis and management of MDS/AML. Array CGH and single nucleotide polymorphism array (SNP-A) are a powerful new tool to assess the chromosomal imbalances at the level of the whole genome. Recently, it has been widely used to overcome the limited capacity of conventional cytogenetic analysis and improve the abnormality detection rate for MDS/AML [@B16],[@B17],[@B18],[@B19]. The cohort of patients with del(5q) and/or -7/del(7q) in this study was characterized by an integrated analysis of karyotype, FISH and array CGH results. Previous cytogenetic studies have shown -5 (monosomy 5) and del(5q) were the most common chromosomal abnormalities in MDS/AML. However, the present study, as well as a recent high-density single nucleotide polymorphism array (SNP-A) study of 1,155 cases with MDS/AML, demonstrated that the cases with putative -5 identified by karyotype analysis actually retained primarily the short arm of chromosome 5 [@B20]. This result confirmed findings in previous studies [@B21],[@B22]. Also, the loss of heterozygosity (LOH) 7 has been detected by SNP-A and showed carrying similar prognosis to -7/del(7q) [@B23],[@B24]. This novel characterization indicates that array CGH is a necessary and powerful complementary tool for the correct diagnosis of MDS/AML patients. Not only does it reveal cryptic CNAs beyond the resolution of G-banding, but it also refines the chromosomal abnormalities found by G-banding and can characterize genomic alterations in cases that cannot be cultured or cultures which fail to grow.

The CDRs on the long arms of chromosomes 5 and 7 underline the importance to pinpoint the candidate genes serving as haploinsufficient tumor suppressors [@B4],[@B5],[@B25]. Previously identified CDRs of 5q were classified into two CDRs consisting of a distal CDR (5q32-q33.1), which has been associated with 5q- syndrome and a proximal CDR (5q31.2-q31.3), which has been related to MDS/AML [@B26]. Interesting genes suggested in these CDRs were *RPS14* located in the 5q distal CDR and *EGR1*, *CTNNA1*, *DIAPH1* and *IL9* found in the 5q proximal CDR, which play roles as a key tumor suppressor genes [@B25],[@B26],[@B27]. Although previous research described a CDR for 7q22 [@B4],[@B6], a recent single nucleotide polymorphism array (SNP-A) analysis in 1,450 patients with myeloid malignancy proposed that the CDRs on 7q involve 7q34 and 7q35-q36 as well [@B28].The interesting genes suggested in these CDRS were *TRIM24*, *SVOPL*, *ATP6V0A4*, *TMEM213*, *KIAA1549*, *ZC3HAV1L*, *ZC3HAV1*, *TTC26*,*UBN2*, *C7orf55*, *LUC7L2*, *KLRG2*, *CLEK2*L, *HIPK2*, *TBXAS1*, *TPK1*, *CNTNAP2*, *MIR548F3*, *C7orf33, CUL1*, *EZH2* [@B28]*.* In our cohort of patients, expanded SRO covering 5q23.2-q33.2 and 7q31.31-q36.1 were identified on chromosomes 5 and 7 encompassing previously identified CDRs of 5q and 7q, which is likely due to the small number of cases.

The high frequency of the losses of 5q and 7q combined with a loss of 17p has been reported in the complex karyotype background [@B12],[@B29]. This suggests the possibility of other genomic aberrations accompanying del(5q) and/or -7/del(7q) that may also contribute to the development or prognosis of MDS/AML. As no difference of SRO on 5q and 7q are shown between the three groups in the present study, further investigation to differentiate the recurrent \'other CNAs\' between the groups was initiated. Group III was a distinctive group that carried the most HN CNAs, cryptic CNAs (\<5Mb) and \'other CNAs\', including recurrent and HN \'other CNAs\', of the three groups in this study. Although group III showed a significantly higher average number of recurrent \'other CNAs\' compared to group I (Table [2](#T2){ref-type="table"}), both groups shared recurrent \'other CNAs\' and target genes (Table [S4](#SM1){ref-type="supplementary-material"}, Figure [S2](#SM1){ref-type="supplementary-material"}). Thus, it can be hypothesized that del(5q) may be the earlier event in the progression of MDS/AML cases with concurrent del(5q) and -7/del(7q), whereas 7q deletion as well as other genomic aberrations may play a secondary role in the late stage of leukemogenesis.

Several studies have already reported the significant genomic aberrations encompassing leukemogenic genes such as gains of 11q23.3 (*MLL*), 8q24.13-q24.21 (*MYC*), 21q22.2 (*EGR*and*TMPRSS2*) and 12p13.32 (*CCND2*) and losses of 9p21.3 (*CDKN2A*), 12p13.31p13.2 (*ETV6*), 16q22.1 (*CBFB*), 17p13 (*TP53*), 17q11.2 (*NF1*), 18p11.2 (*PTPN2*) and 21q22.12 (*RUNX1)*, which were found in our study as well [@B30]-[@B37]. Our study not only identified previously reported tumor-related genes harbored in the recurrent CNAs but also assessed these genes based on three categorized groups: del(5q) (group I), -7/del(7q) (group II), and concurrent del(5q) and del(7q) (group III) (Figure [2](#F2){ref-type="fig"}), even if we have the limitation that LOH cannot be detected by our study. Gains of*PDGFD*, *MLL, ETS1*and *ADAMTS8*and losses of*MANF, TP53*and*WRAP53*were presumed to be highly associated with del(5q) because they were common in both groups I and III. A recent study related to pathogenesis of therapy related myeloid neoplasms (t-MN) with a complex karyotype and del(5q) and/or -7/del(7q) found that *TP53* mutations were pre-existing in hematopoetic stem-cells, and that *TP53* mutated cells survived chemotherapy and radiation therapy for primary cancer to give rise to t-MN. This indicates that aberration of *TP53* may be happened in the early stage of disease and associated with prognosis [@B38]. However, the loss of *ETV6,*a frequent deletion in acute leukemia cases with translocations, was shown to be particularly associated with group III. Recently, the cryptic CNA del(12p), involving the *ETV6* gene as well as point mutation of *ETV6* gene, has been reported in AML and MDS with clinical significance [@B17],[@B39]-[@B41]. It is thought to be a complementary step that, in cooperation with certain critical cytogenetic events such as t(12;21) or +8, drives leukemogenesis. However, in contrast to a study by Wall and colleagues who demonstrated a high association of *ETV6* deletion and monosomy 7 in MDS/AML cases [@B42], all the deletions of *ETV6*in our study were found in group III \[concurrent del(5q) and del(7q)\] and none of the cases were in group II \[-7/del(7q) only)\]. Also, aberrations of *ADCY5, BCL2L14*, *RERG* and *PTPN1*that have been previously reported in MDS and leukemia cases were shown to be highly associated in the cases with concurrent del(5q) and del(7q) (group III) [@B43]-[@B45]. These CNAs or genes may play a secondary role in disease progression and should be further evaluated for their clinical significance and influence on therapeutic approaches in patients with MDS/AML carrying del(5q) and/or -7/del(7q) in large-scale, patient population study.

Conclusion
==========

An integrated analysis combining karyotype, FISH and array CGH results performed on MDS/AML samples with del(5q) and/or -7/del(7q) allowed us to group patients by genomic imbalances and to suggest candidate genes located on chromosomes other than 5 and 7 that may affect the maintenance and progression of a patient\'s malignant phenotype. Group III, with concurrent del(5q) and -7/del(7q), was a distinctive group that carried the most HN CNAs, cryptic CNAs (\<5Mb) and \'other CNAs\', including recurrent and HN \'other CNAs\'. Loss of*TP53*was more highly associated with del(5q) than del(7q). However, the loss of *ETV6* was shown to be particularly associated with concurrent del(5q) and del(7q) (group III). The CNAs or genes, such as *TP53* and *ETV6*, identified in our study may play an important role in the disease progression and should be further evaluated for their clinical significance and influence on therapeutic approaches in patients with MDS/AML carrying del(5q) and/or -7/del(7q) in large scaled patient population study.
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![Map of SRO of chromosomes 5 and 7 in the three groups. A. The SRO of chromosome 5. The SRO of group I is 5q23.2-q33.2 (122,435,964-154,319,730bp: hg18) and \~ 32Mb in size. The SRO of group III is 5q31.1-33.1 (130,562,020-150,625,216bp: hg 18) and \~ 20Mb in size, which is the common SRO of groups I and III of chromosome 5. B. The SRO of chromosome 7. The SRO of group II is 7q22.1-qter (102,913,354-158,816,034bp: hg 18) and \~ 56Mb in size. The SRO of group III is 7q31.31-q36.1 (119,547,309-149,033,790bp: hg 18) and \~ 29Mb in size, which is the common SRO of groups II and III of chromosome 7. Interesting genes in each SRO are listed.](ijmsv12p0719g001){#F1}

![The distribution of the selected interesting tumor-associated genes located in recurrent \'other CNAs\'. A black shadow indicates a gain of genes and a grey shadow indicates a loss of genes. Note that the losses of the 12p13 region encompassing the *ETV6* gene and the 17p13.1 region encompassing the *TP53* gene do not occur simultaneously in group III.](ijmsv12p0719g002){#F2}

###### 

Comparison of complex CNAs between the three groups

                                                                       Group I   Group II   Group III   p value              
  -------------------------------------------------------------------- --------- ---------- ----------- --------- ---------- --------
  Number of cases with HN CNAs / number of total cases in each group   2/6       0/11       8/9         0.0889    ≤ 0.0001   0.1103

###### 

Comparison of \'other CNAs\' between the three groups using several parameters

                                                                    Group I         Group II        Group III       p value              
  ----------------------------------------------------------------- --------------- --------------- --------------- --------- ---------- --------
  Average number of "other CNAs"/case (mean±SEM)                    12.00±5.398     1.818±0.7841    17.44±1.952     0.2916    ≤ 0.0001   0.0230
  Average number of recurrent "other CNAs"/case (mean±SEM)          1.263±0.08163   1.053±0.05263   1.621±0.08011   0.0043    0.0004     0.0892
  Cases with HN "other CNAs"/cases in each group (number /number)   3/6             0/11            8/9             0.2352    ≤ 0.0001   0.0294

SEM: Standard Error of the Mean
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